Hookworm Vaccine Trials Begin at GW

In a pioneering study, infecting healthy adults is the next step toward eradicating the infection. “These past few months have taught me a lot about hookworms, and it’s also given me intriguing insight into my own body and behaviors,” she said. Ms. Markowitz is one of the participants of the Hookworm Study. Check out this article to read more about Ms. Markowitz's experience.

 

Latest News

A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: